Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Although the relationship between increasing age and the prevalence of histologic benign prostatic hyperplasia (BPH), prostate inflammation, high-grade intraepithelial neoplasia, atypical small acinar proliferation, and prostate cancer has been understood for some time, our understanding of the interrelationships between prostate diseases beyond epidemiologic associations is evolving. Furthermore, we are just beginning to unravel how these relationships may affect ageing men, in terms of their effects on bladder function, resultant lower urinary tract symptoms, sexual dysfunction, and overall quality of life. There is increasing evidence of a role for inflammation in the development of prostate cancer and also in precipitating symptoms and acute urinary retention in men with BPH. Furthermore, experimental and clinical trial evidence demonstrates the importance of androgens, particularly dihydrotestosterone, in the development and maintenance of a number of prostate disorders. Although the theoretical role of the 5α-reductase inhibitors in the prevention of prostate cancer was hypothesised almost 20 yr ago, it was not until recently that the Prostate Cancer Prevention Trial demonstrated their benefit. Taken together with their effects on BPH, and putative benefits on chronic prostate inflammation, it is possible that the 5α-reductase inhibitors may have a broader role in the maintenance of prostate health and that they could provide concomitant benefits across a wider spectrum of prostate disease. Such a strategy has profound implications for the screening, detection, and long-term management of prostate disease in ageing men.

Original languageEnglish (US)
Pages (from-to)698-703
Number of pages6
JournalEuropean Urology, Supplements
Volume5
Issue number12
DOIs
StatePublished - Aug 2006

Fingerprint

Prostate
Prostatic Neoplasms
Prostatic Hyperplasia
Inflammation
Oxidoreductases
Maintenance
Lower Urinary Tract Symptoms
Urinary Retention
Dihydrotestosterone
Disease Management
Androgens
Urinary Bladder
Quality of Life
Clinical Trials
Health
Neoplasms

Keywords

  • Benign prostatic hyperplasia
  • Lower urinary tract symptoms
  • Prostate cancer
  • Prostatitis

ASJC Scopus subject areas

  • Urology

Cite this

@article{acc92f0a16ea48e1acb9aee515997fd6,
title = "Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice",
abstract = "Although the relationship between increasing age and the prevalence of histologic benign prostatic hyperplasia (BPH), prostate inflammation, high-grade intraepithelial neoplasia, atypical small acinar proliferation, and prostate cancer has been understood for some time, our understanding of the interrelationships between prostate diseases beyond epidemiologic associations is evolving. Furthermore, we are just beginning to unravel how these relationships may affect ageing men, in terms of their effects on bladder function, resultant lower urinary tract symptoms, sexual dysfunction, and overall quality of life. There is increasing evidence of a role for inflammation in the development of prostate cancer and also in precipitating symptoms and acute urinary retention in men with BPH. Furthermore, experimental and clinical trial evidence demonstrates the importance of androgens, particularly dihydrotestosterone, in the development and maintenance of a number of prostate disorders. Although the theoretical role of the 5α-reductase inhibitors in the prevention of prostate cancer was hypothesised almost 20 yr ago, it was not until recently that the Prostate Cancer Prevention Trial demonstrated their benefit. Taken together with their effects on BPH, and putative benefits on chronic prostate inflammation, it is possible that the 5α-reductase inhibitors may have a broader role in the maintenance of prostate health and that they could provide concomitant benefits across a wider spectrum of prostate disease. Such a strategy has profound implications for the screening, detection, and long-term management of prostate disease in ageing men.",
keywords = "Benign prostatic hyperplasia, Lower urinary tract symptoms, Prostate cancer, Prostatitis",
author = "Claus Roehrborn",
year = "2006",
month = "8",
doi = "10.1016/j.eursup.2006.06.007",
language = "English (US)",
volume = "5",
pages = "698--703",
journal = "European Urology, Supplements",
issn = "1569-9056",
publisher = "Elsevier",
number = "12",

}

TY - JOUR

T1 - Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice

AU - Roehrborn, Claus

PY - 2006/8

Y1 - 2006/8

N2 - Although the relationship between increasing age and the prevalence of histologic benign prostatic hyperplasia (BPH), prostate inflammation, high-grade intraepithelial neoplasia, atypical small acinar proliferation, and prostate cancer has been understood for some time, our understanding of the interrelationships between prostate diseases beyond epidemiologic associations is evolving. Furthermore, we are just beginning to unravel how these relationships may affect ageing men, in terms of their effects on bladder function, resultant lower urinary tract symptoms, sexual dysfunction, and overall quality of life. There is increasing evidence of a role for inflammation in the development of prostate cancer and also in precipitating symptoms and acute urinary retention in men with BPH. Furthermore, experimental and clinical trial evidence demonstrates the importance of androgens, particularly dihydrotestosterone, in the development and maintenance of a number of prostate disorders. Although the theoretical role of the 5α-reductase inhibitors in the prevention of prostate cancer was hypothesised almost 20 yr ago, it was not until recently that the Prostate Cancer Prevention Trial demonstrated their benefit. Taken together with their effects on BPH, and putative benefits on chronic prostate inflammation, it is possible that the 5α-reductase inhibitors may have a broader role in the maintenance of prostate health and that they could provide concomitant benefits across a wider spectrum of prostate disease. Such a strategy has profound implications for the screening, detection, and long-term management of prostate disease in ageing men.

AB - Although the relationship between increasing age and the prevalence of histologic benign prostatic hyperplasia (BPH), prostate inflammation, high-grade intraepithelial neoplasia, atypical small acinar proliferation, and prostate cancer has been understood for some time, our understanding of the interrelationships between prostate diseases beyond epidemiologic associations is evolving. Furthermore, we are just beginning to unravel how these relationships may affect ageing men, in terms of their effects on bladder function, resultant lower urinary tract symptoms, sexual dysfunction, and overall quality of life. There is increasing evidence of a role for inflammation in the development of prostate cancer and also in precipitating symptoms and acute urinary retention in men with BPH. Furthermore, experimental and clinical trial evidence demonstrates the importance of androgens, particularly dihydrotestosterone, in the development and maintenance of a number of prostate disorders. Although the theoretical role of the 5α-reductase inhibitors in the prevention of prostate cancer was hypothesised almost 20 yr ago, it was not until recently that the Prostate Cancer Prevention Trial demonstrated their benefit. Taken together with their effects on BPH, and putative benefits on chronic prostate inflammation, it is possible that the 5α-reductase inhibitors may have a broader role in the maintenance of prostate health and that they could provide concomitant benefits across a wider spectrum of prostate disease. Such a strategy has profound implications for the screening, detection, and long-term management of prostate disease in ageing men.

KW - Benign prostatic hyperplasia

KW - Lower urinary tract symptoms

KW - Prostate cancer

KW - Prostatitis

UR - http://www.scopus.com/inward/record.url?scp=33746704901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746704901&partnerID=8YFLogxK

U2 - 10.1016/j.eursup.2006.06.007

DO - 10.1016/j.eursup.2006.06.007

M3 - Article

AN - SCOPUS:33746704901

VL - 5

SP - 698

EP - 703

JO - European Urology, Supplements

JF - European Urology, Supplements

SN - 1569-9056

IS - 12

ER -